Fate of science "hero" uncertain

Senator Arlen Specter, long-time champion of biomedical research, is facing tough reelection battle

Written byKerry Grens

| 3 min read

It isn't often that citizens from a single state in the union can dramatically shift the fate of research support in the United States, but Pennsylvania voters may have the chance on Tuesday (May 18). They head to the polls in a primary election that will determine whether democratic linkurl:Senator Arlen Specter;http://specter.senate.gov/public/ -- arguably the most celebrated champion of biomedical research in Congress -- will remain in his seat next year.

Arlen Specter
Image: Steve Dietz/Sharp Image

Specter, a decades-long incumbent, is challenged by a comparatively green Congressman, linkurl:Joe Sestak,;http://sestak.house.gov/ currently representing the state in the House of Representatives. Fueled by volleys of television advertising, which highlights Specter's recent switch from the Republican party (which Sestak's camp dubs "opportunistic"), Sestak has made a steady climb in the polls and has become a formidable opponent."We are following this [election] with great interest," said linkurl:Ellen Sigal,;http://www.focr.org/ellen-v-sigal-phd.html the chair of Friends of Cancer Research, a cancer research think tank. Sigal says she's worked with Specter for years. "He's revered in our community," Sigal said. "No one has done as much for biomedical research with as much passion -- and, frankly, delivery, rather than rhetoric." The senator was instrumental in adding $10 billion for the National Institutes of Health to the 2009 stimulus package. In the 1990s he led the charge to double the NIH budget. Most recently, he tucked $500 million for translational research into the healthcare overhaul bill that passed this year. Specter has been both the chairman and ranking member on the appropriations subcommittee for Health and Human Services, which determines the budget for the NIH. "Absent my push I think there's no doubt the funding would go way down," Specter told The Scientist. Research advocates are concerned that Specter might be right. linkurl:Mary Woolley,;http://www.researchamerica.org/mary_woolley the president of Research!America, points out that there's been a recent loss of support for research on Capitol Hill, with Senator Edward Kennedy's death last year and the upcoming retirement of Representative David Obey. "The strong champions for research for health are very few in number in the Senate right now, and really Senator Specter is critical in that regard," Woolley said.The research community could ask for a worse replacement in Joe Sestak, however. In 2005, his daughter was diagnosed with (and has since survived) glioblastoma, and he says the experience inspired him. "Healthcare and the research needed, particularly in cancer, as well as in other areas, is what drove me to Congress with my daughter's brain tumor," Sestak told The Scientist. Sestak has only been in Congress for two terms, but "his voting record in the Congress has been one of support for research generally and especially research for the military and veterans," Woolley said. Sestak was a two star Rear Admiral in the Navy. He has also authored legislation supportive of angel investors and venture capital -- two important funders of early stage biotechnology companies. And, like Specter, Sestak supports embryonic stem cell research.The real blow to the research community could come at the general election later this year, when the Democratic victor faces the likely Republican candidate, Pat Toomey. linkurl:Joanne Carney,;http://www.aaas.org/ScienceTalk/carney.shtml the director of the AAAS Center for Science, Technology and Congress, said the most salient representation of Toomey's tenure in the House was an amendment Toomey sponsored that would have de-funded some NIH grants. "That memory may be a bit raw still within the biomedical research community," Carney said. And according to the latest Rasmussen poll of potential voters, Toomey leads either Democrat by several points.Carney, Woolley and Sigal said they do not endorse candidates.
**__Related stories:__***linkurl:Stem cell bill is back;http://www.the-scientist.com/blog/display/55485/
[27th February 2009]*linkurl:Senate OKs big NIH bump;http://www.the-scientist.com/blog/display/55398/
[4th February 2009]*linkurl:U.S. Senate to okay expanded stem cell bill?;http://www.the-scientist.com/news/display/23895/
[10th July 2006]

Meet the Author

Kerry Grens

Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

View Full Profile

Fate of science "hero" uncertain

The Scientist ARCHIVES

Become a Member of

Meet the Author

Kerry Grens

Related Research Resources

A Stubborn Gene, a Failed Experiment, and a New Path

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Advancing Drug Discovery with Complex Human In Vitro Models

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Maximizing Cancer Research Model Systems

Products

Product News

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies